Our Correspondent
The Subject Expert Committee of Central Drugs Standard Control Organisation (CDSCO) that met on January 1 and 2, 2021 has granted the permission to Cadila Healthcare Ltd for conduct of the Phase III clinical trial of the Novel Corona Virus-2019-nCov-Vaccine it has developed.
The firm initiated Phase-I/II clinical trial in India in more than 1,000 participants which is ongoing. The interim data suggests that the vaccine is safe and immunogenic with three doses when administered intradermally. Accordingly, firm has sought permission to conduct Phase-III clinical trial in 26,000 Indian participants, which has been recommended by the Subject Expert Committee.
The approval for the third phase of trials for Cadila Healthcare Ltd came even as the CDSCO approved vaccines of M/s Serum and M/s Bharat Biotech for restricted use in emergency situation.
India Union Budget was sector diversified and considering the increasing global economic challenges, the India…
MUSCAT: The ‘Who’s Who of Oman Indian s’, which will include detailed information on prominent…
By Joseph Maliakan The Muslims and the nomads in the Himalayan state of Uttarkhand which…
By Joseph Maliakan The Supreme Court on 29 December 2025 in an unprecedented but welcome…
With the overall GDP valued at USD 4. 18 trillion, India has surpassed Japan to…
By Joseph Maliakan The new Bill introduced by the Union government , Viksit Bharat -…
This website uses cookies.